openPR Logo
Press release

Hypercholesterolemia Market size and Key Trends in terms of volume and value 2015 - 2023

Hypercholesterolemia Market size and Key Trends in terms

Increased level of total cholesterol and LDL (bad) cholesterol in the blood leads to hypercholesterolemia. The normal biological range of total blood cholesterol is 140-200 mg/dL. Hypercholesterolemia leads to cardiovascular diseases such as atherosclerosis, stroke etc. Human blood cholesterol mainly consists of High-density lipoprotein (HDL) cholesterol, Low-density lipoprotein (LDL) cholesterol, Very low-density lipoprotein (VLDL) cholesterol. HDL cholesterol is termed as good cholesterol for the body. High level of HDL cholesterol reduces the risk for heart diseases and HDL naturally removes cholesterol from cells by reverse cholesterol transport to the liver. On the other, hand LDL adds to plaque, a hard and dense deposit that blocks the arteries and make the artery wallless flexible. This type of medical condition is termed as atherosclerosis. Clot forms and blocks the narrowed arteries leads to heart attack, stroke and peripheral artery diseases.

Report Overview and TOC @ https://www.transparencymarketresearch.com/hypercholesterolemia-market.html 

Hypercholesterolemia usually result from the grouping of genetic and environmental risk factors. Genetic disorder leads to heterozygous familial hypercholesterolemia. It happens due to the existence of the mutated copy of the LDLR gene (LDL receptor gene). Individuals with the homozygous gene, containing dual copies of the gene mostly suffer from severe cardiovascular diseases in their childhood and people with the heterozygous gene that is with a solitary copy of the gene suffer from cardiac ailment in their 30s or 40s. Hypercholesterolemia due to lifestyle selections includes unhealthy eating habits, lack of exercise, and intake of tobacco smoking strongly hampers the quantity of cholesterol in the blood. However, there are few secondary reasons as well such as diabetes mellitus (Type 2), alcohol intake, obesity, monoclonal gammopathy, dialysis and others.

Request brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8176

The hypercholesterolemia treatment market is increasing at a substantial rate due to technologically advanced diagnosis, government initiatives, improved reimbursement scenario lifestyle changes, rising awareness about different cardiovascular diseases. Treatment for hypercholesterolemia mainly includes intake of statins and opting for a better lifestyle. Factors such as high cost in the diagnosis, lack of awareness and lack of knowledgeable experts for proper diagnosis of the disease are restricting the global market for hypercholesterolemia treatment. North America rules the global market for hypercholesterolemia treatment reason beingincreased incidences of heart diseases and related disorders in the region. Asia, followed by Europe, predicted to witness a high growth rate in coming years in the hypercholesterolemia market.

For Specific and Customized requirements@ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=8176

Developing countries like China and India are also growing fast in these markets by the presence of a large patient pool and growing government initiatives. Hypercholesterolemia Market can be segmented as drug class and geography. Drug class can categorize hypercholesterolemia market as statins, niacin, bile-acid resins, fibric acid derivatives, cholesterol absorption inhibitors. Some of the key players in this Hypercholesterolemia market AbbVie, Inc., AstraZeneca Plc., Amgen, Inc., Eli Lilly and Company, Merck & Co., Novartis AG and Pfizer, Tekmira Pharmaceuticals Corporation.

Pre Book full report@ https://www.transparencymarketresearch.com/hypercholesterolemia-market.html?secure=NTIxNS41&type=PB

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Transparency Market Research

State Tower
90 State Street,
Suite 700,
Albany NY - 12207
United States

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hypercholesterolemia Market size and Key Trends in terms of volume and value 2015 - 2023 here

News-ID: 848895 • Views:

More Releases from Transparency Market Research

Functional Coffee Market Expanding at 7.6% CAGR Through 2035 - By Product Type / By Function | Europe • North America • Asia Pacific
Functional Coffee Market Expanding at 7.6% CAGR Through 2035 - By Product Type / …
The global functional coffee market was valued at US$ 21.5 Bn in 2024 and is projected to reach US$ 48.1 Bn by 2035, expanding at a compound annual growth rate (CAGR) of 7.6% from 2025 to 2035. This steady growth trajectory reflects the strong convergence of coffee consumption habits with rising demand for functional and wellness-oriented beverages. Functional coffee has transitioned from a niche category to a mainstream product offering,
Global Electric Face Cleanser Market Poised for Robust Growth, projected to Reach USD 23.6 Billion by 2036 | Transparency Market Research
Global Electric Face Cleanser Market Poised for Robust Growth, projected to Reac …
The global electric face cleanser market is witnessing a transformative growth phase as consumers increasingly integrate advanced skincare technologies into their daily routines. Valued at USD 9.8 billion in 2025, the market is projected to expand significantly and reach USD 23.6 billion by 2036, growing at a healthy compound annual growth rate (CAGR) of 8.6% from 2026 to 2036. This growth trajectory underscores the rising importance of personal care technology,
Asthma and COPD Drugs Market to Reach US$ 82.2 Billion by 2036, Growing at 5.7% CAGR Driven by Rising Respiratory Disease Burden
Asthma and COPD Drugs Market to Reach US$ 82.2 Billion by 2036, Growing at 5.7% …
The global asthma and COPD drugs market demonstrated strong fundamentals in 2025, with a valuation of US$ 44.7 Bn, reflecting the essential and recurring nature of respiratory therapeutics. Supported by a growing patient base and continuous pharmaceutical innovation, the market is projected to reach US$ 82.2 Bn by 2036, expanding at a compound annual growth rate (CAGR) of 5.7% from 2026 to 2036. This growth trajectory highlights the increasing reliance on
Low-Alcohol Beverages Market Outlook 2035: Global Industry Set to Expand from US$ 2.1 Bn to US$ 4.6 Bn by 2035 at 7.5% CAGR
Low-Alcohol Beverages Market Outlook 2035: Global Industry Set to Expand from US …
The global low-alcohol beverages market is undergoing a structural transformation as consumers increasingly prioritize health, moderation, and mindful drinking without sacrificing taste or social experiences. Valued at US$ 2.1 billion in 2024, the market is projected to reach US$ 4.6 billion by 2035, expanding at a healthy CAGR of 7.5% from 2025 to 2035. This sustained growth reflects changing lifestyle preferences, generational shifts in alcohol consumption, and continuous innovation by

All 5 Releases


More Releases for Hypercholesterolemia

Homozygous Familial Hypercholesterolemia Market Outlook 2024-2034
Introduction Homozygous familial hypercholesterolemia (HoFH) is a rare, life-threatening genetic disorder characterized by extremely high cholesterol levels from birth. Patients with HoFH are at a very high risk of premature atherosclerotic cardiovascular disease (ASCVD), often developing complications as early as childhood. While the condition is rare-affecting approximately 1 in 160,000 to 300,000 individuals globally-it has become a major focus for pharmaceutical innovation due to the severity of the disease and the
Hypercholesterolemia Treatment Market Reviews Analysis Report 2024
Hypercholesterolemia Treatment Market to reach over USD 36.37 billion by the year 2031 - Exclusive Report by InsightAce Analytic According to a new report by InsightAce Analytic, the "Hypercholesterolemia Treatment Market" in terms of revenue was estimated to be worth $27.9 billion in 2023 and is poised to reach $36.37 billion by 2031, growing at a CAGR of 3.43% from 2024 to 2031. Get a free Sample copy of the
Hypercholesterolemia Treatment Market: Transforming Lives: Impact of Hypercholes …
Newark, New Castle, USA: The "Hypercholesterolemia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Hypercholesterolemia Treatment Market: https://www.growthplusreports.com/report/hypercholesterolemia-treatment-market/8571 This latest report researches the industry structure, sales, revenue,
Hypercholesterolemia Treatment Market Insights, Forecast to 2031
The report extensively examines the global Hypercholesterolemia Treatment market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Hypercholesterolemia Treatment . For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers influencing the global market
Heterozygous Familial Hypercholesterolemia (heFH) Therapeutics - Pipeline Analys …
Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic disorder that affects the body’s ability to control cholesterol. It is characterized by very high LDL (low density lipoprotein) cholesterol (above 190 for adults or above 160 for children) and family history of high cholesterol, heart disease or stroke. Download the sample report @ https://www.pharmaproff.com/request-sample/1135 A very high level of LDL from birth leads to a twenty-fold increase in the risk of premature
Hypercholesterolemia Market Global Analysis & 2023 Forecast Report
Increased level of total cholesterol and LDL (bad) cholesterol in the blood leads to hypercholesterolemia. The normal biological range of total blood cholesterol is 140-200 mg/dL. Hypercholesterolemia leads to cardiovascular diseases such as atherosclerosis, stroke etc. Human blood cholesterol mainly consists of High-density lipoprotein (HDL) cholesterol, Low-density lipoprotein (LDL) cholesterol, Very low-density lipoprotein (VLDL) cholesterol. HDL cholesterol is termed as good cholesterol for the body. High level of HDL cholesterol